XY Capital’s Moderna MRNA Stock Holding History

XY Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,600	Closed	-$329K	–	153
2025 Q1	$329K	Buy	11,600 +7,000	+152%	+$248K	0.09%	142
2024 Q4	$191K	Buy	+4,600	New	+$220K	0.09%	146

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

XY Capital's MRNA Position: Q2 2025 in Review

XY Capital sold out of Moderna (MRNA) in Q2 2025, closing a stake of 5,807 shares — an estimated $165K sold.

XY Capital first reported a position in MRNA in Q4 2024 and held it in 2 quarters. The position peaked at $165K in Q1 2025. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

XY Capital reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
XY Capital sold 5,807 Moderna shares in Q2 2025, an estimated $165K.
XY Capital first reported a position in Moderna in Q4 2024 and held it in 2 quarters.
XY Capital's Moderna position peaked at $165K in Q1 2025.
674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on XY Capital's 13F filing for Q2 2025, filed 14 Aug 2025.